List of Excipients in Branded Drug EMPLICITI

Empliciti Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Empliciti (elotuzumab) is an intravenous monoclonal antibody approved for multiple myeloma in combination with immunomodulatory agents and dexamethasone. Its excipient system is conventional for a lyophilized antibody: sucrose for protein stabilization, citrate for pH control, and polysorbate 80 for interfacial protection. The commercial opportunity is less likely to come from novel excipient composition and more likely to come from biosimilar development, manufacturing efficiency, ready-to-use presentation, administration-time reduction, and differentiated combination products.

Empliciti has 12-year U.S. reference-product exclusivity from its first FDA approval in 2015, subject to the statutory biologics framework. That period runs to approximately 2027, although patent protection and regulatory exclusivity must be assessed separately. Empliciti is a biologic and is not listed in the FDA Orange Book; relevant biologic competition is addressed through the Purple Book and the Biologics Price Competition and Innovation Act pathway.[1-3]

What excipients are used in Empliciti?

Empliciti is supplied as a sterile, preservative-free lyophilized powder for intravenous infusion. The U.S. prescribing information identifies the following inactive ingredients:

Excipient	Primary formulation function
Sucrose	Stabilizes the antibody during freezing, drying, storage, and reconstitution
Sodium citrate	Buffering and pH control
Citric acid	Buffering and pH adjustment
Polysorbate 80	Limits adsorption and aggregation at air-liquid and container-liquid interfaces

The product is supplied in single-dose 300 mg and 400 mg vials. It is reconstituted with Sterile Water for Injection and further diluted in either 0.9% sodium chloride injection or 5% dextrose injection before intravenous administration.[1]

Why is sucrose used in Empliciti?

Sucrose is a nonreducing disaccharide commonly used in lyophilized monoclonal antibody formulations. During lyophilization, it can replace part of the hydration shell surrounding the protein and reduce structural damage caused by freezing and water removal. It also contributes to the formation of an amorphous glass that immobilizes the antibody during storage.

For a commercial biosimilar or follow-on product, sucrose is unlikely to be a strong differentiation point by itself. A developer would generally need to demonstrate comparable stability, aggregation behavior, subvisible particle levels, potency, and immunogenicity risk rather than simply replicate the excipient identity.

What is the role of citrate and polysorbate 80?

The citrate system maintains a pH range compatible with antibody stability and intravenous administration. Polysorbate 80 reduces protein adsorption to vial, syringe, tubing, and infusion-bag surfaces. It also limits agitation-induced aggregation.

Polysorbate 80 creates a secondary development issue: it can undergo oxidation and hydrolysis, generating degradation products that may affect protein quality. A competing developer could evaluate polysorbate 20, alternative surfactants, or lower surfactant concentrations, but any change would require a substantial comparability package. The burden would include forced-degradation studies, particulate analysis, extractables and leachables assessment, and evaluation of anti-drug antibody risk.

What is the Empliciti formulation and administration strategy?

Empliciti uses a vialed lyophilized presentation rather than a liquid ready-to-use formulation. The design has several technical advantages:

• Improved long-term stability compared with many liquid antibody formulations.
• Reduced risk of aggregation during shipment and storage.
• A conventional hospital pharmacy workflow.
• Compatibility with both saline and dextrose dilution.
• No preservative-related tolerability or compatibility issue.

The main commercial disadvantages are preparation time, reconstitution steps, cold-chain dependence, infusion-center labor, and the risk of dose-preparation error. These factors define the most credible product-improvement opportunities.

Product attribute	Empliciti position	Commercial implication
Dosage form	Lyophilized powder	Stable but requires reconstitution
Route	Intravenous infusion	Infusion-center administration required
Vial sizes	300 mg and 400 mg	Supports weight-based dosing but can create vial-waste exposure
Preservative	None	Suitable for single-dose parenteral use
Diluent compatibility	0.9% sodium chloride or 5% dextrose	Broad institutional compatibility
Storage	Refrigerated biologic storage	Requires cold-chain logistics
Administration	Premedication and infusion monitoring required	Labor and chair-time burden

The product is dosed by body weight, which creates opportunities for vial-optimization software, pharmacy compounding protocols, and reduced-waste purchasing strategies. Any commercial proposal involving altered vial sizes would need to balance manufacturing cost against the value of reducing discarded drug.

What formulation patents protect Empliciti?

Empliciti is protected through a biologic patent and regulatory framework rather than an Orange Book listing. The relevant protection may include claims directed to:

1. The anti-SLAMF7 antibody or antibody variants.
2. Antibody sequence and binding characteristics.
3. Nucleic acids, vectors, and host cells used to produce the antibody.
4. Methods of treating multiple myeloma.
5. Combination treatment with lenalidomide, pomalidomide, and dexamethasone.
6. Manufacturing and purification processes.
7. Formulation or storage conditions, where separately claimed.

The FDA Orange Book generally does not list patents for therapeutic biologics such as elotuzumab. Patent disputes involving a biosimilar applicant would generally proceed under the BPCIA patent-exchange and litigation framework rather than the Hatch-Waxman Paragraph IV process used for small-molecule drugs.[2,3]

Is there an Empliciti Paragraph IV challenge?

A conventional Paragraph IV challenge is not the expected statutory mechanism for elotuzumab because Empliciti is a biologic licensed under the Public Health Service Act. A biosimilar applicant would instead submit a section 351(k) application and may participate in the BPCIA patent-disclosure process.

This distinction matters commercially. A competitor cannot assume that a small-molecule-style ANDA strategy will provide an abbreviated route to market. It must establish biosimilarity through analytical, functional, pharmacokinetic, immunogenicity, and, where required, clinical evidence.

When does Empliciti lose exclusivity?

Milestone	Date or period
First FDA approval	November 2015
U.S. reference-product exclusivity	Approximately 12 years from first approval
Earliest statutory biosimilar submission window	Approximately four years after first approval
Reference-product exclusivity endpoint	Approximately November 2027
Patent expiry	Depends on issued patents, patent-term adjustment, patent-term extension, and settlements

The 2018 approval of Empliciti with pomalidomide and dexamethasone expanded the approved treatment setting but did not create a new 12-year reference-product exclusivity period.[1,2] A method-of-use patent could still delay a specific indication even after composition-related protection expires.

Biosimilar launch timing will depend on the surviving patent claims, any BPCIA litigation, settlement terms, pediatric exclusivity, and the commercial decision to launch with a restricted label or carve out patented uses.

What method-of-use patents and combination claims matter?

Empliciti’s clinical value is tied to combination therapy. The relevant commercial risk is therefore not limited to the antibody molecule. Method-of-use claims may cover:

• Elotuzumab with lenalidomide and dexamethasone.
• Elotuzumab with pomalidomide and dexamethasone.
• Treatment of patients previously exposed to lenalidomide or a proteasome inhibitor.
• Treatment after disease progression on prior therapy.
• Specific dosing schedules or patient-selection criteria.

A biosimilar could seek approval for the molecule while carving out a patented indication. That approach would reduce litigation exposure but may also reduce market access if the carved-out indication accounts for a material share of use.

What is the FDA regulatory status of Empliciti?

Empliciti is FDA-approved for adult patients with multiple myeloma in combination regimens. The label includes:

• Elotuzumab plus lenalidomide and dexamethasone for patients who have received one to three prior therapies.
• Elotuzumab plus pomalidomide and dexamethasone for patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or after the last therapy.[1]

The product requires premedication because infusion-related reactions are a recognized risk. This requirement increases the operational burden of a competing product but also creates an opportunity for a formulation or delivery system that reduces infusion reactions, infusion duration, or premedication intensity. Such a claim would require clinical evidence and would not follow automatically from a change in excipients.

What commercial opportunities exist for Empliciti excipients?

Biosimilar and interchangeable-product development

The largest opportunity is a 351(k) biosimilar. A biosimilar sponsor could initially match the established excipient system to reduce formulation risk, then pursue a differentiated formulation only if there is a clear clinical or operational benefit.

Potential value drivers include:

• Lower acquisition cost.
• Reduced infusion-center preparation time.
• Lower vial waste.
• Improved stability under controlled room-temperature conditions.
• Lower aggregation or particle burden.
• Simplified dilution and administration.
• Interchangeability, if supported by the required evidence and approved by FDA.

Interchangeability could improve pharmacy substitution potential, but payer adoption and contracting may be more important than the designation alone.

Ready-to-use liquid formulation

A liquid formulation could eliminate reconstitution and reduce pharmacy labor. The main technical barriers are liquid-state aggregation, oxidation, viscosity, container compatibility, and long-term stability.

A successful liquid product could be supplied in a ready-to-dilute vial, prefilled syringe, or infusion-compatible container. The regulatory path would depend on whether the product is an originator reformulation, biosimilar, or separate biologic product.

Alternative surfactants and lower-particle formulations

Polysorbate 80 is widely accepted but can create degradation and particulate-control challenges. A developer could investigate:

• Polysorbate 20.
• Poloxamers.
• Low-surfactant systems.
• Antioxidant strategies.
• Improved container closure systems.
• Silicone-oil-reduced delivery components.

These approaches have potential value in reducing visible and subvisible particles, but the development package must show that the change does not impair potency or increase immunogenicity.

Vial-size and dose-waste optimization

Weight-based dosing can produce unused drug when the prescribed dose does not align with available vial sizes. Commercial opportunities include:

• Additional vial strengths.
• Smaller supplemental vials.
• Dose-band protocols.
• Pharmacy inventory tools.
• Contract manufacturing for optimized presentations.

The economics depend on actual dosing distribution, vial discard rates, wholesaler pricing, and hospital reimbursement. A smaller vial may reduce waste but increase packaging, testing, and distribution cost.

Extended-storage and distribution products

A formulation with longer refrigerated stability or limited room-temperature excursion tolerance could reduce supply-chain losses. The commercial benefit is strongest for hospitals and specialty distributors that manage frequent inventory movement.

Any claim of improved thermal stability requires data across real-time, accelerated, freeze-thaw, agitation, light-exposure, and shipping-stress conditions. It also requires control of aggregation, charge variants, potency, and particles.

How strong is the Empliciti patent estate?

The estate should be assessed in four layers:

Layer	Likely commercial relevance
Composition and sequence claims	Highest barrier to a molecule-level competitor before expiry
Manufacturing claims	Can increase biosimilar development and scale-up cost
Formulation claims	May constrain excipient substitutions or liquid reformulations
Method-of-use claims	Can affect label scope and indication-specific launch timing

Composition claims generally provide the strongest protection if valid and enforceable. Formulation claims are more valuable when they cover a necessary stability solution rather than a routine excipient combination. Method-of-use claims may delay access to particular patient populations but are less likely to block an entire biosimilar launch if a clean label carve-out is available.

Patent strength depends on claim scope, written-description support, prosecution history, priority dates, terminal disclaimers, patent-term adjustment, and prior-art exposure. A definitive freedom-to-operate position requires a current patent-family and litigation review.

What patent litigation affects Empliciti?

Empliciti is subject to biologic patent-risk analysis rather than the standard Orange Book certification process. Relevant litigation questions include:

• Whether a biosimilar applicant has provided the required BPCIA notices.
• Which patent families the reference-product sponsor identifies.
• Whether the dispute concerns composition, manufacturing, formulation, or use.
• Whether the biosimilar seeks approval for all labeled indications.
• Whether a settlement creates an agreed launch date.
• Whether a state or federal competition issue affects the settlement.

No commercial forecast should assume immediate market entry upon statutory exclusivity expiry. Patent settlements, manufacturing readiness, FDA review timing, and payer contracting can move launch timing in either direction.

How does Empliciti compare with competing multiple-myeloma biologics?

Product	Active ingredient	Route	Excipient opportunity	Competitive issue
Empliciti	Elotuzumab	IV infusion	Ready-to-use formulation, reduced waste, biosimilar	Mature combination product and infusion burden
Darzalex	Daratumumab	IV or subcutaneous	Delivery-system and administration-time differentiation	Strong subcutaneous franchise
Sarclisa	Isatuximab	IV infusion	Infusion-time and stability improvements	Competes in later-line combination therapy
Blenrep	Belantamab mafodotin	IV infusion	Antibody-drug-conjugate formulation and handling	Different mechanism and safety profile

Empliciti competes against drugs with greater commercial emphasis on subcutaneous or shorter administration. This reduces the value of an excipient-only improvement. The strongest product strategy would combine formulation enhancement with a meaningful administration or health-economic benefit.

What revenue exposure does Empliciti create?

Bristol Myers Squibb reports major products separately in public financial filings, but Empliciti is not generally disclosed as a standalone revenue category in the same way as the company’s largest products.[4] That limits precise revenue attribution.

Commercial exposure is concentrated in:

• Multiple-myeloma treatment algorithms.
• Combination-regimen persistence.
• Physician preference for established antibody combinations.
• Infusion-center capacity.
• Payer coverage for later-line therapy.
• Competition from daratumumab and isatuximab.
• Future biosimilar pricing.

A biosimilar developer should model price erosion by regimen, not only by molecule. If Empliciti use is concentrated in a narrow later-line population, a lower-cost biosimilar may expand access without producing the same substitution volume seen in high-volume primary-care biologics.

What is the best commercial strategy for an Empliciti follow-on product?

The lowest-risk strategy is an analytically matched lyophilized biosimilar using the established sucrose-citrate-polysorbate platform. The higher-value strategy is a differentiated product with one or more of the following:

1. Ready-to-dilute liquid presentation.
2. Lower vial waste.
3. Longer allowable storage excursions.
4. Reduced preparation time.
5. Lower particulate burden.
6. Shorter infusion or reduced premedication burden, supported by clinical evidence.
7. Interchangeability designation.
8. Contracting targeted to specialty pharmacies and hospital systems.

An excipient change alone is unlikely to create durable market power. The commercial proposition must connect formulation performance to reduced total treatment cost or improved infusion-center throughput.

Key Takeaways

• Empliciti contains sucrose, citrate buffer components, and polysorbate 80 in a lyophilized intravenous formulation.
• The formulation is conventional and optimized for antibody stability rather than administration convenience.
• Empliciti is a biologic, so Orange Book and Paragraph IV frameworks do not apply in the ordinary small-molecule sense.
• U.S. reference-product exclusivity runs approximately to November 2027, while patent expiry may differ.
• The strongest follow-on opportunities are biosimilar development, ready-to-use presentation, vial-waste reduction, and administration-time improvement.
• Formulation patents may create incremental barriers, but composition, manufacturing, and method-of-use claims must be analyzed separately.
• Competitive pressure from daratumumab and isatuximab reduces the commercial value of an excipient change without an operational or clinical benefit.
• Empliciti revenue is not typically disclosed as a standalone major-product category, limiting precise exposure estimates.

FAQs

Can Empliciti be reformulated with polysorbate 20?

Yes, a developer could evaluate polysorbate 20, but the change would require extensive comparability and stability testing. The substitute must preserve potency, aggregation control, particle limits, and immunogenicity performance.

Is Empliciti eligible for biosimilar approval?

Yes. Elotuzumab is a biologic eligible for development under the FDA section 351(k) biosimilar pathway, subject to reference-product exclusivity and applicable patent barriers.[2,3]

Can a generic manufacturer file an ANDA for Empliciti?

No. Empliciti is a biologic, not a conventional small-molecule drug. The relevant abbreviated pathway is a biosimilar application under section 351(k), not an ANDA under section 505(j).

Would a liquid Empliciti product receive new exclusivity?

A reformulated product may receive regulatory or patent protection depending on its approval basis and claims, but a new liquid presentation does not automatically receive a new 12-year reference-product exclusivity period.

What is the most valuable excipient opportunity for Empliciti?

The highest-value opportunity is a formulation that materially reduces preparation, waste, storage, or administration costs. A simple excipient substitution without a measurable operational benefit is unlikely to support premium pricing or durable differentiation.

References

1. U.S. Food and Drug Administration. (2024). Empliciti (elotuzumab) prescribing information. Bristol-Myers Squibb Company.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

3. U.S. Food and Drug Administration. (2023). Questions and answers on biosimilar development and the BPCI Act.

4. Bristol Myers Squibb. (2024). Annual report and Form 10-K.